Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 5 , Pages 473-482 , September 2009

Prostate tumor alignment and continuous, real-time adaptive radiation therapy using electromagnetic fiducials: Clinical and cost-utility analyses

  • Martin M. Quigley, M.D., MBA, MHA

      Affiliations

    • Calypso Medical Technologies, Seattle, WA 98121, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-206-254-0600; fax: +1-206-254-0606
    • ,
  • Timothy P. Mate, M.D.

      Affiliations

    • Swedish Cancer Institute, Seattle, WA 98121, USA
    • ,
  • John E. Sylvester, M.D.

      Affiliations

    • Swedish Cancer Institute, Seattle, WA 98121, USA
    • Seattle Prostate Institute, Seattle, WA 98121, USA

Received 9 February 2008 ,Revised 19 April 2008 ,Accepted 19 April 2008.

References 

  1. American Cancer Society. Cancer Facts and Figures 2006. http://www.cancer.org/downloads/STT/CAFF2007PWSecured.pdfAccessed January 20, 2008
  2. Foroudi F, Tyldesley S, Barbera L, et al. Evidence-based estimate of appropriate radiotherapy utilization rate for prostate cancer. Int J Radiat Oncol Biol Phys. 2003;55:51–63
  3. NOMOS Radiation Oncology (Image Guided Radiation Therapy). http://www.nasmedical.com/binary?id=2764Accessed January 20, 2008
  4. BrainLAB AG. IGRT ExacTrac Brochure. http://www.brainlab.com/download/pdf/IGTExacTracBrochure.pdfAccessed January 20, 2008
  5. Konski A, Watkins-Bruner D, Feigenberg S. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys. 2006;66:408–415
  6. Berger AP, Gozzi C, Steiner H, et al. Complication rate of transrectal ultrasound guided prostate biopsy: A comparison among three protocols with 6, 10, and 15 cores. J Urol. 2004;171:1478–1480
  7. Henry AM, Wilkinson C, Wylie JP, et al. Trans-perineal implantation of radio-opaque treatment verification markers into the prostate: An assessment of procedure related morbidity, patient acceptability, and accuracy. Radiother Oncol. 2004;73:57–59
  8. Barry MJ, Fowler FJ, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia (The Measurement Committee of the American Urological Association). J Urol. 1992;148:1549–1557
  9. Kupelian P, Willoughby T, Mahadevan A, et al. Multi-institutional clinical experience with the Calypso System in localization and continuous, real-time monitoring of the prostate gland during external radiotherapy. Int J Radiat Oncol Biol Phys. 2007;67:1088–1098
  10. Purdy JA. Current ICRU definitions of volumes: Limitations and future directions. Semin Radiat Oncol. 2004;14:27–40
  11. Pickett B, Roach M, Verhey L, et al. The value of nonuniform margins for six-field conformal irradiation of localized prostate cancer. Intl J Radiat Oncol Biol Phys. 1995;32:211–218
  12. Roach M, Pickett B, Rosenthal SA, et al. Defining treatment margins for six field conformal irradiation of localized prostate cancer. Int J Radiat Oncol Biol Phys. 1994;28:267–275
  13. Schaly B, Bauman GS, Song W, et al. Dosimetric impact of image-guided 3D conformal radiation therapy of prostate cancer. Phys Med Biol. 2005;50:3083–3101
  14. Beard CJ, Lamb C, Buswell L, et al. Radiation-associated morbidity in patients undergoing small-field external beam irradiation for prostate cancer. Int J Radiation Oncol Biol. 1998;41:257–262
  15. Roach M. Reducing the toxicity associated with the use of radiotherapy in men with localized prostate cancer. Urol Clin N Am. 2004;31:353–366

 Conflict of interest notification: All funding for the research reported in this manuscript was provided by Calypso Medical Technologies, Seattle, WA, manufacturer of the Calypso® 4D Localization System with Beacon® transponders used in this research. MMQ is a paid consultant of Calypso Medical Technologies. Aequitas is a San Diego, CA-based consulting firm retained by Calypso Medical Technologies to perform a cost-utility analysis from the clinical trial data reported herein. T.P.M. and J.E.S. have received and continue to receive funding from Calypso Medical Technologies to support their ongoing research.

PII: S1078-1439(08)00115-4

doi: 10.1016/j.urolonc.2008.04.017

Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 5 , Pages 473-482 , September 2009

Article Tools

* Image Usage & Resolution